Sphaeranthus indicus

The dried flower heads of an aromatic herb that grows in damp ground and rice-field margins across India and Sri Lanka. Ayurveda calls it gorakhmundi, and the traditional uses run to indigestion, liver complaints, skin and inflammation.

The characteristic constituent of the flower heads is 7-hydroxyfrullanolide, a sesquiterpene lactone, alongside flavonoids and essential oils; commercial extracts are graded on it. In cells it blocks IKK-β phosphorylation and NF-κB translocation, and it reduces TNF-α and IL-6 output from human immune cells; given orally it is active in rodent inflammation models. That is the whole mechanistic story, and it is worth being precise about where it stops. None of that work is human, nobody has shown that an oral dose reaches human gut tissue at a concentration that does anything, and the traditional digestive use has never been given a mechanism at all. Sesquiterpene lactones are bitter, so a plain bitter-herb effect on digestive secretion is at least as plausible as anything molecular, and that has not been tested either.

Used traditionally to support comfortable digestion. In RICH it makes up part of the 300 mg herbal blend and is there for the traditional pairing with haritaki, not for any metabolic effect.

Anyone who wants the complete traditional herb pair rather than haritaki on its own. Not for people with ragweed, mugwort or other Asteraceae allergy, not in pregnancy or breastfeeding, not for anyone avoiding animal-derived ingredients, and not for anyone buying RICH in the hope of a metabolic or body-composition effect. There is none on offer and none claimed.

Take with the meal, as with the rest of RICH. Bitter herbs are traditionally taken with or shortly before food rather than hours away from it, and that is how this capsule is designed to be used. Nothing needs to be separated from S. indicus specifically, though the tannins it shares the blend with do want distance from iron supplements.

Nothing you will notice. At its share of a 300 mg blend, inside a capsule carrying four other actives, there is no plausible sensation attributable to Sphaeranthus indicus in particular and no timeline worth giving you.

The human evidence for Sphaeranthus indicus is almost entirely one programme of trials on a proprietary blend of S. indicus flower head and Garcinia mangostana fruit rind extracts, an ingredient RICH does not contain. Stern et al. (2013, Obesity 21(5):921–7, doi 10.1002/oby.20211, PMID 23784895) randomised 60 adults with BMI 30–40 to 400 mg of the blend or placebo twice daily for eight weeks alongside a 2,000 kcal diet and 30 minutes of walking five days a week. Kudiganti et al. (2016, Lipids in Health and Disease 15:136, PMID 27558585) repeated the design over 16 weeks in 60 overweight adults with a mean BMI of 28.3, with 57 completing; both trials reported statistically significant differences versus placebo on their primary endpoint and no supplementation-related adverse events. We do not reproduce their body-weight figures here: this is a food supplement, the trials were of a different product, and amounts of weight change are not something we will put on an ingredient page. Maunder et al. (2020, Diabetes, Obesity and Metabolism 22(6):891–903, PMID 31984610) is the independent systematic review and meta-analysis of 54 randomised trials; it grouped S. indicus with G. mangostana among the preparations supported by three trials or fewer, cautioned that the small number of studies, generally poor methodological quality and poor reporting of the interventions warrant care, and concluded there is currently insufficient evidence to recommend any of the herbal medicines reviewed for weight loss. Saiyed et al. (2015, Food and Chemical Toxicology 78:122–9, PMID 25680508) reported oral LD50 above 5,000 mg/kg and dermal LD50 above 2,000 mg/kg in Sprague-Dawley rats and a 13-week subchronic NOAEL of 1,000 mg/kg/day — for the blend, not for S. indicus alone. Mechanistic work on 7-hydroxyfrullanolide (Fonseca et al., European Journal of Pharmacology, 2010 and 2011) shows inhibition of IKK-β phosphorylation and NF-κB translocation and reduced TNF-α and IL-6 production, with oral activity in rodent inflammation models; there is no human clinical data on the isolated compound. What is not supported: any weight, fat-loss or body-composition claim for S. indicus in this product, which contains neither the partner herb nor the studied blend, and any human digestive claim at all, which rests entirely on Ayurvedic tradition plus preclinical anti-inflammatory work.